U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2023
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On April 10, 2023, AnPac Bio-Medical Science Co., Ltd. (the “Company”) engaged Zhong Yin Law Firm as the Company’s legal counsel with respect to laws of the People’s Republic of China (the “PRC”, which, for the purposes of this report, excludes the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan). Effective April 10, 2023, Zhong Lun Law Firm will no longer serve as the Company’s PRC legal Counsel.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | AnPac Bio-Medical Science Co., Ltd. |
| | |
| | By: | /s/Haohan Xu |
| | Name: | Haohan Xu |
| | Title: | Co-Chief Executive Officer |
| | | |
| Dated: April 10, 2023 | | |
